BOARD OF DIRECTORS

  • BS, MBA

    CEO, Movius

    Previously MD at 247.AI and VP at Trimble Navigation

    Worked across early to late stage start-ups and a Fortune 100 corporation

  • PhD, GradDipAppFin

    CEO, Magic Pudding

    Non-Executive Director, TechnologyOne

    Member, Brisbane Angels

    15 years experience in the biotech sector and 3 years of VC experience

  • AO, MBBS, MD, FRACP, FAA

    Executive Director of the Victor Chang Cardiac Research Institute for 26 years

    40 years of experience in clinical cardiovascular research

    Co-Founder of Infensa Bioscience

  • BCom, MBA

    Chair, George Clinical

    Previously CEO of Chiltern International and VP of Global Operations at Charles River Labs

    20 years of experience in the pharmaceutical services sector

  • Trustee of The Kinghorn Foundation

    Director of Saluda Medical Inc

    Has worked with several large not-for-profit medical research institutions

    Has worked across early-stage med tech and biotechnology companies

  • BSc, PhD

    CEO & MD, Alsonex

    Previously CEO & MD of Pharmaxis (14 years) & Promics (now part of Teva)

    More than 25 years of experience in the pharmaceutical sector

OUR TEAM

Chief Executive Officer

  • Business Founder, Infensa Bioscience

    Previously Founder, CEO, CSO, and VP of Protagonist Therapeutics

    Total of 7 drug candidates in human clinical trials

    30 years experience in the biotech sector

Chief Scientific Officer

  • BSc PhD FAA FAAM

    Co-Founder, Infensa Bioscience

    Sole founder and inaugural CSO, Vestaron Corporation

    Group Leader, Institute for Molecular Bioscience

    Inventor on 16 patents

Chief Operating Officer

  • Previously COO and Company Secretary at Lowy Institute, Cancer Council and Prime Partners

    Solicitor with experience across private, government and NFP sectors.

    Young Australian Lawyer of the Year 2009.

Head of Project Management

  • 30+ years in pharmaceutical industry — 20 years at Novo Nordisk and 10+ years split between Genentech & Mylan Pharmaceuticals

    Led numerous Discovery Projects into IND-Enabling Studies & Phase I Clinical Trials. Also led various projects through Phase II & Phase III towards registration

    As Lead Scientist invented Anamorelin®, approved in Japan for cancer cachexia

    Global Project Lead for Semglee®, the first approved interchangeable long-acting Insulin

CMC Director

  • Previously Head of Manufacturing Sciences and Technology at Lonza Biologics Guangzhou

    13 years at CSL / CSL Behring

    20 years of experience in biologics product development and manufacture

Head of Biology

  • BSc PhD

    Co-Founder, Infensa Bioscience

    Group Leader, Institute for Molecular Bioscience at the University of Queensland

LEAD SCIENTISTS

Head of Chemistry

  • PhD in Chemical Biology from the Max-Planck Institute for Molecular Physiology in Germany.

    Worked as a peptide chemist in top research institutes in Germany, Switzerland and Australia, conducting academic and industry-funded research developing innovative chemistry for medicinal or biotechnological applications

    15 years experience in peptide and protein chemistry, including fine-tuning of cyclic peptide structure, synthesis of entire proteins and disulfide-rich toxins and improvement of drug-like properties of bioactive peptides

Head of Cell Biology

  • Master of Biotechnology from the University of Queensland

    Research Assistant for Professor Melissa Little

    Senior Research Assistant and Laboratory Manager for Associate Professor Nathan Palpant

    Experienced in induced pluripotent stem cells, with a focus in cardiac and kidney differentiation

    Contributor to publications in high-impact journals such as Nature, Cell Stem Cell and Circulation

  • Medicinal Chemist with a PhD in Drug Design and Development from the University of Queensland

    PhD focused on relaxin-3 ligand development to modulate food intake

    Worked at Protagonist Therapeutics with a focus on peptide drug development

    Driven to pursue novel therapeutics addressing unmet medical needs

  • BSc (Hons) in Biochemistry and PhD in Molecular Pharmacology from the University of Queensland

    PhD focused on understanding the interaction between acid-sensing ion channel 1a and its modulator, PcTx1, for future therapeutic development

    Worked in France on the R&D phase of the FP7 European Venomics project, producing venom-peptides for drug discovery screening

    Over 10 years of experience in working with acid-sensing ion channels and their modulators

    Skilled in production and electrophysiological characterisation of novel therapeutic candidates